Bronchopulmonary Dysplasia - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2017, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. The predisposing factors include congenital heart disease and severe respiratory or lung infection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 9 and 2 respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchopulmonary Dysplasia - Overview
Bronchopulmonary Dysplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchopulmonary Dysplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
Airway Therapeutics LLC
Chiesi Farmaceutici SpA
MediPost Co Ltd
Meridigen Biotech Co Ltd
Syntrix Biosystems Inc
Therabron Therapeutics Inc
Bronchopulmonary Dysplasia - Drug Profiles
AT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pneumostem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapies for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmonary Dysplasia - Dormant Projects
Bronchopulmonary Dysplasia - Discontinued Products
Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants
May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM'for Treating Lung Disease
Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth
Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform
Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate
Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial
Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform
Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'
Feb 06, 2014: Stem cells to treat lung disease in preterm infants
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H1 2017
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H1 2017
Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H1 2017
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H1 2017
Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics Inc, H1 2017
Bronchopulmonary Dysplasia - Dormant Projects, H1 2017
Bronchopulmonary Dysplasia - Discontinued Products, H1 2017